Targeting hyperactivation of the AKT survival pathway to overcome therapy resistance of melanoma brain metastases

Brain metastases are the most common cause of death in patients with metastatic melanoma, and the RAF-MEK-ERK and PI3K-AKT signaling pathways are key players in melanoma progression and drug resistance. The BRAF inhibitor vemurafenib significantly improved overall survival. However, brain metastases...

Descripción completa

Detalles Bibliográficos
Autores principales: Niessner, Heike, Forschner, Andrea, Klumpp, Bernhard, Honegger, Jürgen B., Witte, Maria, Bornemann, Antje, Dummer, Reinhard, Adam, Annemarie, Bauer, Jürgen, Tabatabai, Ghazaleh, Flaherty, Keith, Sinnberg, Tobias, Beck, Daniela, Leiter, Ulrike, Mauch, Cornelia, Roesch, Alexander, Weide, Benjamin, Eigentler, Thomas, Schadendorf, Dirk, Garbe, Claus, Kulms, Dagmar, Quintanilla-Martinez, Leticia, Meier, Friedegund
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Blackwell Publishing Ltd 2013
Materias:
Clinical Cancer Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3797558/
https://www.ncbi.nlm.nih.gov/pubmed/24133630
http://dx.doi.org/10.1002/cam4.50

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3797558/
https://www.ncbi.nlm.nih.gov/pubmed/24133630
http://dx.doi.org/10.1002/cam4.50

Ejemplares similares